Weight loss injections are prescription medicines with specific approved uses, precautions and monitoring requirements in Australia. Their suitability depends on an individual medical assessment. This educational overview explains the difference between ingredients and brands, the limits of trial results, and safety questions to discuss with a prescriber. It does not recommend a medicine or offer prescribing services.
Online discussions often mix diabetes treatment, weight management and medicine prices. Keep those questions separate. A product's name alone does not establish why it was prescribed or whether its cost will be subsidised.
Semaglutide, liraglutide and tirzepatide are ingredients used in Australian prescription injections with weight-management indications. Brand-specific product information sets out who can be treated and under what conditions.
| Ingredient | Example Australian brand | Relevant distinction |
|---|---|---|
| Semaglutide | Wegovy | Has a weight-management indication under its product information |
| Liraglutide | Saxenda | Has a weight-management indication under its product information |
| Tirzepatide | Mounjaro | Has weight-management and type 2 diabetes indications under its product information |
| Semaglutide | Ozempic | Its Australian indications concern type 2 diabetes and associated kidney disease; it is a different product from Wegovy |
For the individual product context, see our Australian Mounjaro guide and Australian Ozempic guide. This overview describes the distinctions without choosing a treatment.
Semaglutide and liraglutide act at the glucagon-like peptide-1 receptor, usually shortened to GLP-1. Tirzepatide acts at both GIP and GLP-1 receptors. These pathways influence appetite and glucose regulation. The medicines can also slow the passage of food out of the stomach.
They are not insulin, and they are not interchangeable pen for pen. Product strengths, dosing instructions and approved patient groups differ. This adult overview does not reproduce prescribing criteria for every indication or give instructions for children and adolescents.
Oral prescription medicines are also used in weight management, with different mechanisms and precautions. A clinician assesses those options in the context of health history. Non-prescription supplements and products advertised online should not be assumed to have the same evidence or regulatory status as an approved medicine.
A prescribing assessment considers the product's approved indication alongside your medical history, existing treatment and circumstances. Eligibility cannot be established from an online weight calculation alone.
A clinician may ask about previous weight-management treatment, diabetes, digestive symptoms, pancreatitis, gallbladder disease, kidney problems and relevant eye conditions. Tell them about all medicines, including insulin, supplements and products obtained online. The current product information determines which precautions apply to a particular medicine.
Pregnancy, breastfeeding and plans to become pregnant need an explicit discussion. The Australian leaflets for Wegovy and Mounjaro advise against use during pregnancy. Product-specific stopping intervals and contraception advice differ, so obtain a written plan from the prescriber. Tirzepatide can affect oral contraceptive absorption; ask a doctor or pharmacist about the precautions in its current leaflet.
The clinician may arrange tests when indicated by your history. A fasting glucose test or an HbA1c test answers a glucose question, rather than independently establishing whether a weight-management medicine is suitable. A general blood panel cannot replace the prescribing assessment.
Randomised trials can show how a medicine performed in a defined group under a study protocol. They do not predict an individual's weight change, side effects or long-term treatment needs.
In the STEP 1 trial, Wilding and colleagues studied semaglutide alongside a lifestyle intervention in adults with overweight or obesity who did not have diabetes. At 68 weeks, the treatment-policy analysis found a mean body-weight reduction of 14.9% with semaglutide 2.4 mg weekly, compared with 2.4% with placebo. Gastrointestinal adverse events occurred, and some participants discontinued treatment because of them.
In SURMOUNT-1, Jastreboff and colleagues studied tirzepatide in adults with obesity, or overweight with a weight-related complication, without diabetes. At 72 weeks, the treatment-regimen analysis found mean weight reductions of 15.0%, 19.5% and 20.9% with the respective weekly 5, 10 and 15 mg doses, compared with 3.1% with placebo. The trial also recorded adverse events and treatment discontinuations.
These were different studies, with their own populations and protocols. Comparing separate headline percentages does not establish which treatment is appropriate for someone. Dose, treatment duration, diabetes status and whether an analysis includes treatment discontinuation all affect how results should be read.
Both trials were industry funded. Their published methods, adverse events and limitations matter alongside the weight results. An informed discussion should include those details rather than treating a before-and-after image or a promotional number as evidence of an expected result.
Digestive side effects can occur with these medicines, including nausea, vomiting, diarrhoea and constipation. The likelihood and severity differ by product, dose and individual circumstances.
Persistent vomiting or diarrhoea can cause dehydration and affect kidney function. Contact the treating clinician if symptoms prevent normal drinking or eating, continue or worsen. Do not assume significant symptoms are an unavoidable part of treatment that must be tolerated without review.
Product leaflets describe serious problems that need medical attention, including pancreatitis, gallbladder problems and allergic reactions. Severe, persistent abdominal pain, particularly with vomiting or pain extending to the back, warrants urgent assessment. Trouble breathing or swelling of the face or throat requires emergency care.
The TGA updated class warnings in July 2026 about a rare, serious eye disorder called non-arteritic anterior ischaemic optic neuropathy, or NAION. Sudden loss of vision or rapidly worsening eyesight requires urgent medical attention. This warning does not mean that every visual symptom has the same cause.
Low blood glucose is a concern particularly when certain medicines are used with insulin or sulfonylureas. Tell your prescriber about those treatments and ask for monitoring and symptom instructions. Any dose adjustment belongs with the treating clinician.
Tell every procedural team about these medicines before anaesthesia or deep sedation. The TGA warns that delayed stomach emptying can leave food in the stomach despite usual fasting, creating a risk of inhaling stomach contents.
The anaesthetist and prescriber should provide the plan for your procedure. Do not choose your own stopping interval or assume an instruction for one product applies to another. Tell the team about digestive symptoms and the timing of the last dose.
| Product | PI starting dose | PI maintenance context |
|---|---|---|
| Mounjaro | 2.5 mg weekly for 4 weeks, then 5 mg weekly | 5, 10 or 15 mg weekly; increases of 2.5 mg require at least 4 weeks at the current dose |
| Wegovy | 0.25 mg weekly, with escalation over 16 weeks | Recommended 2.4 mg weekly; current PI permits a conditional 7.2 mg option for some adults |
| Ozempic, type 2 diabetes | 0.25 mg weekly for 4 weeks, then 0.5 mg weekly | Glycaemic-control section permits 1 mg then 2 mg, with at least 4 weeks at each preceding dose |
The Wegovy 7.2 mg option applies only to adults with an initial BMI of at least 30, after at least 4 weeks at 2.4 mg, if needed. Its PI specifies three 2.4 mg injections and reduction to 2.4 mg if no additional clinical improvement occurs. This is not the dose limit for every indication or age group.
Starting doses, increases and missed-dose instructions are product specific. Follow the current prescription and leaflet. Do not copy another person's schedule, combine products or change treatment because a social-media account describes a particular approach. If a dose is missed or a pen is damaged, ask the pharmacist or prescriber what applies.
The TGA has warned about imported, unregistered GLP-1 products promoted online. Such products may not meet Australian standards for quality, safety and effectiveness. An online seller's description does not establish the contents or approval status. A pharmacist can help check a supplied product and its storage instructions.
TGA approval does not automatically mean that a medicine is subsidised through the Pharmaceutical Benefits Scheme. PBS access depends on the product, indication and current restrictions.
The PBS item 12075M lists Ozempic for type 2 diabetes under Authority Required restrictions, with a general patient charge of $25.00. A fresh medicine search on 16 October 2026 returned no Wegovy or tirzepatide listing. A diabetes-related listing does not establish subsidy for weight management. Check the current PBS Schedule with the prescriber or pharmacist for the exact prescription and clinical circumstances. Recommendations made by the Pharmaceutical Benefits Advisory Committee also need to be distinguished from a listing that has taken effect.
Private prices can vary with the product, prescribed strength, pack and pharmacy. The following are published Chemist Warehouse pack-price examples, checked October 2026, rather than a national monthly price. Ask for a dated quote for the actual prescription, then clarify consultation fees, follow-up and other costs separately. A program fee may include services beyond the medicine itself.
| Exact product | Published pack price | Source |
|---|---|---|
| Mounjaro KwikPen 2.5 mg, four-dose pen | $279.99 | Chemist Warehouse |
| Mounjaro KwikPen 5 mg, four-dose pen | $389.99 | Chemist Warehouse |
| Wegovy FlexTouch 2.4 mg-dose, 3 mL pen | $369.99 | Chemist Warehouse |
| Ozempic 1.34 mg/mL, 3 mL pen | $144.99 private | Chemist Warehouse |
The TGA shortage register checked on 16 October 2026 contained no Mounjaro or Wegovy entry in the returned results. It identified a discontinued older Ozempic presentation and its replacement. Register findings cannot guarantee a pharmacy has stock. Ask the pharmacist about the exact prescribed presentation and any supply problem before the next dose is due.
Ongoing review should consider the reason for treatment, tolerability, nutrition and relevant health measures. A change on the scales is only part of that assessment.
Tell the clinician if reduced appetite makes it difficult to eat adequately. They may arrange dietitian support or investigations appropriate to symptoms. Our guide to dietitian appointments explains how that care is organised, without deciding which treatment you should receive.
The STEP 1 extension observed weight regain after semaglutide and the study lifestyle intervention stopped. It supports discussing longer-term treatment and follow-up before a change, but it cannot predict an individual's experience after stopping. Make that plan with the prescriber rather than stopping, restarting or changing a dose yourself.
Glucose monitoring may be appropriate for a separate clinical reason, particularly in diabetes treatment. A sensor is not a treatment for obesity or a substitute for medicine follow-up. Our explanation of blood tests and continuous glucose monitoring describes their different measurement roles.
No. They contain the same active ingredient, semaglutide, but are different products with different approved uses and prescribing instructions. The current Australian Ozempic information concerns type 2 diabetes and associated kidney disease. Wegovy has weight-management indications. A prescriber should explain the exact product and reason for treatment.
No. Trial doses are part of a research protocol, not personal prescribing instructions. Starting, increasing or restarting a medicine requires the product-specific plan from your clinician. Tolerability, other treatment and missed doses can affect that plan. Ask your prescriber or pharmacist rather than copying a published trial or another patient.
No. Registration and subsidy are separate. A TGA-approved product may have a PBS listing for a particular indication, with restrictions, or require a private prescription in other circumstances. Ask the prescriber or pharmacist to check the current PBS Schedule and your expected cost for the actual prescription.
The current Australian Wegovy and Mounjaro leaflets advise against use during pregnancy. Pregnancy planning, breastfeeding and contraception need a product-specific discussion with the prescriber. Contact them promptly if pregnancy occurs or is suspected. Do not apply one medicine's stopping interval or contraception instructions to another product.
START YOUR BASELINE
Vively includes a Baseline Health Check with 70+ biomarkers, a results report and practitioner support in the $99 a month membership. No minimum term.
Explore Baseline Health CheckSubscribe to our newsletter & join a community of 30,000+ Aussies
Start a PCOS assessment with your GP. Learn which blood tests matter, when ultrasound or AMH is useful, and how contraception affects results.
Know what to do about an unexpected high blood sugar reading, when to seek urgent help, and which everyday habits support longer-term glucose care.
.avif)
.svg)
Vively is a general wellness platform and does not provide medical advice, diagnosis, or treatment. Any information, insights or guidance offered through our app, website, programs, or coaches is for educational and informational purposes only and should not be considered a substitute for professional medical advice or care. Always consult a qualified healthcare provider before making any health-related decisions.
We acknowledge the Traditional Custodians of the lands where we live and work, the Gadigal of the Eora Nation. We pay our respects to their Elders past and present.
Share
Tweet
Share
